Suven Life Sciences Ltd
NSE: SUVEN BSE: 530239
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.[1]
₹253
52W: ₹124 — ₹303
PE 0 · Book ₹57 · +344% vs bookMarket Cap₹6,676 Cr
Stock P/E—Price to Earnings
ROCE4.72%Return on Capital
ROE4.76%Return on Equity
Div. Yield0%Face Value ₹1
Strengths
- +Company is almost debt free.
- +Promoter holding has increased by 2.79% over last quarter.
Weaknesses
- −Stock is trading at 4.09 times its book value
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of -12.0% over past five years.
- −Company has a low return on equity of -4.50% over last 3 years.
- −Debtor days have increased from 63.7 to 77.5 days.
- −Working capital days have increased from 3,407 days to 9,419 days
Shareholding Pattern
Promoters70.15%
FIIs0.91%
DIIs4.62%
Public24.32%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.26% | 70.26% | 70.26% | 70.26% | 70.26% | 67.36%▼2.9 | 67.36% | 70.15%▲2.8 |
| FIIs | 0.45% | 0.33%▼0.1 | 0.34%▲0.0 | 0.25%▼0.1 | 0.58%▲0.3 | 1.17%▲0.6 | 1.07%▼0.1 | 0.91%▼0.2 |
| DIIs | 1.05% | 1.05% | 1.05% | 0.01%▼1.0 | 0.03%▲0.0 | 3.39%▲3.4 | 3.39% | 4.62%▲1.2 |
| Public | 28.21% | 28.34%▲0.1 | 28.35%▲0.0 | 29.47%▲1.1 | 29.12%▼0.3 | 28.07%▼1.1 | 28.18%▲0.1 | 24.32%▼3.9 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 |
| Expenses | 12 | 9 | 11 | 16 | 15 | 16 | 16 | 19 | 18 | 18 |
| Operating Profit | -9 | -7 | -10 | -14 | -13 | -15 | -14 | -18 | -15 | -16 |
| OPM % | -376% | -287% | -999% | -530% | -826% | -1014% | -749% | -1947% | -530% | -1066% |
| Net Profit | -5 | -3 | -8 | -11 | -13 | -15 | -15 | -15 | -13 | -11 |
| EPS ₹ | -0.22 | -0.14 | -0.35 | -0.51 | -0.61 | -0.69 | -0.68 | -0.68 | -0.59 | -0.42 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹7Cr, up 0% YoY. OPM at -886%.
Debt Position
Borrowings at ₹17Cr. Debt-to-equity ratio: 0.01x. Healthy balance sheet.
Capex Cycle
CWIP at ₹4Cr (5% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 4.62% (+4.54pp change). FIIs: 0.91% (+0.43pp change). Promoters hold 70.15%.
Margin & Efficiency
ROCE declining from 31% (Mar 2015) to -5% (Mar 2026). Working capital days: 9419.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 14 May
- Announcement under Regulation 30 (LODR)-Monitoring Agency Report 14 May - Crisil monitoring report for quarter ended March 31, 2026 shows no deviations in Rs 85,764.02 lakh preferential issue use.
- Grant Of Stock Options 13 May - Committee approved grant of 1,33,200 stock options under SLSL ESOP 2020 at ₹55 each.
- Outcome Of The Meeting Of Board Held On May 13, 2026 13 May
- Board Meeting Outcome for Outcome Of Board Meeting Of Suven Life Sciences Limited Held On May 13, 2026 13 May - Board approved FY26 audited results, fixed 37th AGM on 25 August 2026, and noted exchange fine waivers.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse